Yahoo India Web Search

Sign In

Search results

  1. irp.nih.gov › pi › anish-thomasAnish Thomas, MBBS, M.D. | Principal Investigators | NIH ...

    Nov 9, 2023 · Anish Thomas, M.D. is a medical oncologist who specializes in the treatment of thoracic cancers. He received his medical degree and postgraduate training in Internal Medicine from St. John's Medical College, Bangalore, India, following which he completed residency in Internal Medicine from State University of New York Upstate Medical University ...

  2. ccr.cancer.gov › staff-directory › anish-thomasAnish Thomas, MBBS, M.D. | Center for Cancer Research

    National Cancer Institute. Building 10 Room 4-5330. Bethesda, MD 20892. 240-760-7343. anish.thomas@nih.gov. Senior Investigator. Developmental Therapeutics Branch. RESEARCH SUMMARY.

    • anish thomas nih1
    • anish thomas nih2
    • anish thomas nih3
    • anish thomas nih4
    • anish thomas nih5

  3. irp.nih.gov › catalyst › 25Newest Lasker Clinical Research Scholar: Anish Thomas, M.D.

    Apr 8, 2022 · The newest Lasker Clinical Research Scholar, Anish Thomas, conducts clinical research on small-cell lung cancer, the most lethal form of lung cancer. EDUCATION: St. John’s Medical College, Bangalore, India (M.B.B.S. and M.D.)

  4. ccr.cancer.gov › news › articleAnish Thomas explains the challenges and goals of his small ...

    Nov 15, 2021 · Anish Thomas, M.B.B.S., M.D., Lasker Clinical Research Scholar in the Developmental Therapeutics Branch, studies small cell lung cancer (SCLC). For Lung Cancer Awareness Month, Thomas describes his current research interests and his goals to help improve the lives of patients with SCLC – the most lethal type of lung cancer.

  5. pubmed.ncbi.nlm.nih.gov › 38897168Microenvironment shapes small-cell lung cancer neuroendocrine ...

    Jun 18, 2024 · Electronic address: anish.thomas@nih.gov. PMID: 38897168. DOI: 10.1016/j.xcrm.2024.101610. Abstract. Small-cell lung cancer (SCLC) is the most fatal form of lung cancer.

  6. pubmed.ncbi.nlm.nih.gov › 33848478Therapeutic targeting of ATR yields durable regressions in ...

    Apr 12, 2021 · Small cell neuroendocrine cancers (SCNCs) are recalcitrant cancers arising from diverse primary sites that lack effective treatments. Using chemical genetic screens, we identified inhibition of ataxia telangiectasia and rad3 related (ATR), the primary activator of the replication stress response, an ….

  7. www.nih.gov › news-events › nih-research-mattersTargeted treatments for small-cell lung cancer

    Apr 27, 2021 · A research team led by Drs. Anish Thomas from NIH’s National Cancer Institute (NCI) and Craig Thomas from NIH’s National Center for Advancing Translational Sciences (NCATS) used a rapid drug-screening process to test almost 2,500 approved and investigational cancer drugs.